|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
US5132405A
(en)
|
1987-05-21 |
1992-07-21 |
Creative Biomolecules, Inc. |
Biosynthetic antibody binding sites
|
|
US5091513A
(en)
|
1987-05-21 |
1992-02-25 |
Creative Biomolecules, Inc. |
Biosynthetic antibody binding sites
|
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
DE60129799T2
(de)
|
2000-03-31 |
2008-04-30 |
The General Hospital Corp., Boston |
Verfahren zur steigerung des haarwuchses durch wnt polypeptid
|
|
US20030044409A1
(en)
|
2001-05-01 |
2003-03-06 |
Carson Dennis A. |
Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
US8093357B2
(en)
|
2002-03-01 |
2012-01-10 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
US7355008B2
(en)
|
2003-01-09 |
2008-04-08 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
US7960512B2
(en)
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
ATE466106T1
(de)
|
2003-10-10 |
2010-05-15 |
Deutsches Krebsforsch |
Zusammensetzungen für die diagnose und therapie von erkrankungen, die im zusammenhang mit einer anomalen expression von futrinen (r-spondinen) stehen
|
|
JP2007512846A
(ja)
|
2003-12-04 |
2007-05-24 |
ゼンコー・インコーポレイテッド |
増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物
|
|
DE102004050620A1
(de)
|
2004-10-13 |
2006-04-20 |
Eberhard-Karls-Universität Tübingen |
Monoklonaler Antikörper gegen Frizzled-Rezeptoren
|
|
AU2005335714B2
(en)
|
2004-11-10 |
2012-07-26 |
Macrogenics, Inc. |
Engineering Fc antibody regions to confer effector function
|
|
JP2008528010A
(ja)
|
2005-01-31 |
2008-07-31 |
アブリンクス ナームローゼ フェンノートシャップ |
重鎖抗体の可変ドメイン配列を作出する方法
|
|
AU2006230413B8
(en)
|
2005-03-31 |
2011-01-20 |
Xencor, Inc |
Fc variants with optimized properties
|
|
DE102005035568A1
(de)
|
2005-07-25 |
2007-02-01 |
M-Phasys Gmbh |
Frizzled 9 als Biomarker für Substrukturen des humanen Gehirns
|
|
PL2578685T3
(pl)
|
2005-08-23 |
2020-01-31 |
The Trustees Of The University Of Pennsylvania |
Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
|
|
US8221751B2
(en)
|
2006-06-21 |
2012-07-17 |
Oncotherapy Science, Inc. |
Tumor-targeting monoclonal antibodies to FZD10 and uses thereof
|
|
EP2548576B1
(en)
|
2006-08-14 |
2016-11-30 |
Chugai Seiyaku Kabushiki Kaisha |
Diagnosis of cancer using anti-desmoglein-3 antibodies
|
|
ES2610474T3
(es)
|
2007-01-11 |
2017-04-27 |
Michael Bacher |
Diagnóstico y tratamiento de la enfermedad de Alzheimer y otras enfermedades neurodegenerativas causantes de demencia
|
|
WO2008093646A1
(ja)
|
2007-02-01 |
2008-08-07 |
National University Corporation NARA Institute of Science and Technology |
Wntシグナル伝達系活性化ペプチド
|
|
EP2331136B1
(en)
|
2008-09-26 |
2018-01-10 |
OncoMed Pharmaceuticals, Inc. |
Frizzled-binding agents and uses thereof
|
|
JO3382B1
(ar)
|
2008-12-23 |
2019-03-13 |
Amgen Inc |
أجسام مضادة ترتبط مع مستقبل cgrp بشري
|
|
US8642339B2
(en)
|
2009-02-03 |
2014-02-04 |
Koninklijke Nederlandse Akademie Van Wetenschappen |
Culture medium for epithelial stem cells and organoids comprising the stem cells
|
|
EP2412800A1
(en)
|
2010-07-29 |
2012-02-01 |
Koninklijke Nederlandse Akademie van Wetenschappen |
Liver organoid, uses thereof and culture method for obtaining them
|
|
WO2010092457A1
(en)
|
2009-02-10 |
2010-08-19 |
Nokia Corporation |
Method, apparatus and computer program product for transfer of capability support information in a multi-rat environment
|
|
EP2305274A1
(en)
|
2009-09-21 |
2011-04-06 |
Centre National de la Recherche Scientifique (CNRS) |
Use of WNT stimulators for treating demyelinating diseases
|
|
MX2012006593A
(es)
|
2009-12-09 |
2012-06-28 |
Bayer Pharma AG |
Anticuerpos anti-c4.4a y usos de los mismos.
|
|
CN102971337B
(zh)
|
2010-04-01 |
2016-09-21 |
昂考梅德药品有限公司 |
卷曲蛋白结合药剂及其应用
|
|
WO2011130624A2
(en)
|
2010-04-16 |
2011-10-20 |
Immune Disease Institute, Inc. |
Sustained polypeptide expression from synthetic, modified rnas and uses thereof
|
|
EP2857499A1
(en)
|
2010-10-01 |
2015-04-08 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
LT2691417T
(lt)
|
2011-03-29 |
2018-10-25 |
Roche Glycart Ag |
Antikūno fc variantai
|
|
US10086043B2
(en)
|
2011-04-03 |
2018-10-02 |
The General Hospital Corporation |
Efficient protein expression in vivo using modified RNA (MOD-RNA)
|
|
GB201106395D0
(en)
|
2011-04-14 |
2011-06-01 |
Hubrecht Inst |
Compounds
|
|
PT3682905T
(pt)
|
2011-10-03 |
2022-04-07 |
Modernatx Inc |
Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
|
|
ES2769786T3
(es)
|
2011-10-14 |
2020-06-29 |
Recordati Ag |
Anticuerpos y métodos para enfermedades relacionadas con la vía Wnt
|
|
WO2013071047A1
(en)
|
2011-11-11 |
2013-05-16 |
Children's Medical Center Corporation |
Compositions and methods for in vitro transcription of rna
|
|
WO2013078199A2
(en)
|
2011-11-23 |
2013-05-30 |
Children's Medical Center Corporation |
Methods for enhanced in vivo delivery of synthetic, modified rnas
|
|
BR112014020233A2
(pt)
|
2012-02-28 |
2017-07-04 |
Irm Llc |
seleção de paciente com câncer para administração de inibidores sinalizantes wnt usando status de mutação rnf43
|
|
CN104411338A
(zh)
|
2012-04-02 |
2015-03-11 |
现代治疗公司 |
用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
|
|
WO2014023709A1
(en)
|
2012-08-09 |
2014-02-13 |
Roche Glycart Ag |
Asgpr antibodies and uses thereof
|
|
WO2014093924A1
(en)
|
2012-12-13 |
2014-06-19 |
Moderna Therapeutics, Inc. |
Modified nucleic acid molecules and uses thereof
|
|
PT2922554T
(pt)
|
2012-11-26 |
2022-06-28 |
Modernatx Inc |
Arn modificado nas porções terminais
|
|
WO2014164253A1
(en)
|
2013-03-09 |
2014-10-09 |
Moderna Therapeutics, Inc. |
Heterologous untranslated regions for mrna
|
|
BR112016024525A2
(pt)
|
2014-04-21 |
2017-10-10 |
Abbvie Stemcentrx Llc |
novos anticorpos anti-rnf43 e métodos de uso
|
|
JP6796059B2
(ja)
|
2014-09-12 |
2020-12-02 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
Wntシグナリングアゴニスト分子
|
|
AU2015340056A1
(en)
|
2014-10-27 |
2017-05-25 |
Agency For Science, Technology And Research |
Anti-TIM-3 antibodies
|
|
WO2016073879A2
(en)
|
2014-11-06 |
2016-05-12 |
Scholar Rock, Inc. |
Transforming growth factor-related antibodies and uses thereof
|
|
EP3221361B1
(en)
|
2014-11-19 |
2021-04-21 |
Genentech, Inc. |
Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
|
|
SG11201708491PA
(en)
|
2015-04-17 |
2017-11-29 |
Merrimack Pharmaceuticals Inc |
Combination treatments with seribantumab
|
|
JP7296728B2
(ja)
|
2015-10-23 |
2023-06-23 |
メルス ナムローゼ フェンノートシャップ |
癌の成長を抑制する結合分子
|
|
MY207684A
(en)
|
2015-12-08 |
2025-03-12 |
Regeneron Pharma |
Compositions and methods for internalizing enzymes
|
|
US20170349659A1
(en)
|
2016-06-03 |
2017-12-07 |
The Board Of Trustees Of The Leland Stanford Junior University |
Wnt signaling agonist molecules
|
|
AU2017363309A1
(en)
|
2016-11-23 |
2019-07-11 |
Bioverativ Therapeutics Inc. |
Mono- and bispecific antibodies binding to coagulation factor IX and coagulation factor X
|
|
WO2018107116A1
(en)
|
2016-12-09 |
2018-06-14 |
Abbvie Stemcentrx Llc |
Methods of reducing toxicity of antibody drug conjugates, and compositions produced thereby
|
|
JP7617603B2
(ja)
|
2017-01-11 |
2025-01-20 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
R-スポンジン(rspo)サロゲート分子
|
|
AU2018211985B2
(en)
|
2017-01-26 |
2025-02-13 |
Surrozen Operating, Inc. |
Tissue-specific Wnt signal enhancing molecules and uses thereof
|
|
US20200123256A1
(en)
|
2017-05-02 |
2020-04-23 |
Chugai Seiyaku Kabushiki Kaisha |
Cytotoxicity-inducing therapeutic agent
|
|
GB201708330D0
(en)
|
2017-05-24 |
2017-07-05 |
Koninklijke Nederlandse Akademie Van Wetenschappen |
Fusion protein for enhancing intestinal regeneration
|
|
JP7418332B2
(ja)
|
2017-12-19 |
2024-01-19 |
スロゼン オペレーティング, インコーポレイテッド |
抗フリズルド抗体及び使用方法
|
|
CN111699003B
(zh)
|
2017-12-19 |
2024-05-03 |
瑟罗泽恩奥普瑞汀公司 |
抗lrp5/6抗体和使用方法
|
|
CN118271444A
(zh)
|
2017-12-19 |
2024-07-02 |
瑟罗泽恩奥普瑞汀公司 |
Wnt替代分子和其用途
|
|
AU2019297522B2
(en)
|
2018-07-05 |
2026-04-23 |
Surrozen Operating, Inc. |
Multi-specific Wnt surrogate molecules and uses thereof
|
|
JP2021530223A
(ja)
*
|
2018-07-09 |
2021-11-11 |
スロゼン, インコーポレイテッド |
組織特異性Wntシグナル増強分子及びその使用
|
|
US20220064337A1
(en)
|
2018-12-19 |
2022-03-03 |
Surrozen, Inc. |
Antigen binding formats for receptor complexes
|
|
AU2020221797A1
(en)
|
2019-02-11 |
2021-08-12 |
Surrozen Operating, Inc. |
Modulation of WNT signalling in ocular disorders
|
|
WO2020185960A1
(en)
|
2019-03-11 |
2020-09-17 |
Surrozen, Inc. |
Modulation of wnt signaling in gastrointestinal disorders
|
|
US20220175884A1
(en)
|
2019-04-02 |
2022-06-09 |
Surrozen Operating, Inc. |
Modulation of wnt signaling in auditory disorders
|
|
KR20220024460A
(ko)
|
2019-06-11 |
2022-03-03 |
안틀라 테라퓨틱스 아이엔씨. |
다가 fzd 및 wnt 결합 분자 및 이의 용도
|
|
US11050604B2
(en)
|
2019-07-01 |
2021-06-29 |
Rampart Communications, Inc. |
Systems, methods and apparatuses for modulation-agnostic unitary braid division multiplexing signal transformation
|
|
US20230138045A1
(en)
|
2020-02-24 |
2023-05-04 |
Surrozen Operating, Inc. |
Wnt super agonists
|
|
WO2022104280A1
(en)
|
2020-11-16 |
2022-05-19 |
Surrozen Operating, Inc. |
Liver-specific wnt signal enhancing molecules and uses thereof
|
|
JP7891006B2
(ja)
|
2021-03-10 |
2026-07-15 |
スロゼン オペレーティング, インコーポレイテッド |
胃腸障害におけるwntシグナル伝達のモジュレーション
|
|
EP4401841A4
(en)
|
2021-09-14 |
2025-07-02 |
Surrozen Operating Inc |
MODULATION OF WNT SIGNALING IN PULMONARY DISORDERS
|
|
CA3240866A1
(en)
|
2021-12-17 |
2023-06-22 |
Surrozen Operating, Inc. |
Wnt-surrogate agents and methods for lacrimal gland regeneration
|